C19orf43 Inhibitors
C19orf43 inhibitors are a class of compounds that interact with cellular signaling pathways to indirectly reduce the functional activity of C19orf43. The mechanism of each inhibitor is unique, but they all converge on the principle of pathway-specific inhibition that in turn affects the activity of C19orf43. For example, LY294002 and Wortmannin both target the PI3K/Akt pathway, a critical signaling route for cell survival and growth. By inhibiting PI3K, these compounds prevent downstream Akt activation, which could indirectly inhibit C19orf43 if its activity is dependent on signals propagated through Akt.
On the other hand, compounds such as PD98059 and U0126 are specific to the MAPK/ERK pathway, another vital route for cell signaling involved in proliferation and differentiation. By inhibiting upstream kinases MEK1 and MEK2, these inhibitors reduce ERK activation. IfC19orf43's functions are connected to the ERK pathway, their inhibition could result in decreased C19orf43 activity. Similarly, inhibitors such as SB203580 and SP600125 target stress-activated MAPK pathways, namely p38 and JNK, respectively. These pathways are vital for cellular responses to environmental stress, and if C19orf43 is involved in these responses, the inhibition of p38 or JNK would likely reduce its activity.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
A specific inhibitor of phosphoinositide 3-kinases (PI3Ks). By blocking PI3Ks, LY294002 prevents the phosphorylation and activation of Akt, leading to reduced cell proliferation and survival. If C19orf43 functions downstream of Akt, its activity would be indirectly inhibited due to the suppression of Akt signaling. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Another PI3K inhibitor that covalently binds to and inhibits the activity of PI3Ks, leading to the inhibition of the PI3K/Akt pathway. This blockade results in decreased survival signals, which could indirectly inhibit C19orf43 activity if it relies on Akt-mediated signaling for its function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
An inhibitor of mitogen-activated protein kinase kinase (MEK), which is upstream of extracellular signal-regulated kinase (ERK). By inhibiting MEK, PD98059 reduces ERK pathway activity, which could decrease C19orf43 activity if it is regulated by the ERK signaling cascade. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
A selective inhibitor of both MEK1 and MEK2, leading to the inhibition of the MAPK/ERK pathway. This suppression could result in reduced activity of C19orf43 if it is involved in or affected by ERK-mediated cellular processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
A specific inhibitor of p38 MAPK. By inhibiting p38 MAPK, SB203580 disrupts cellular responses to stress and cytokines, potentially decreasing the activity of C19orf43 if it is involved in these stress response pathways. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
An inhibitor of c-Jun N-terminal kinase (JNK), which modulates cellular stress responses. Inhibition of JNK can lead to reduced transcriptional activity of stress response genes, potentially diminishing C19orf43 activity if it is stress-responsive. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
An mTOR inhibitor, which results in the blockade of the mTORC1 pathway. This inhibition can lead to reduced protein synthesis and cell proliferation. Should C19orf43 function depend on mTORC1 activity, its activity would be indirectly decreased by rapamycin. | ||||||
Palbociclib | 571190-30-2 | sc-507366 | 50 mg | $321.00 | ||
A cyclin-dependent kinase (CDK) 4/6 inhibitor, which leads to cell cycle arrest in the G1 phase. This could indirectly inhibit C19orf43 activity if it is involved in cell cycle progression. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
A proteasome inhibitor that prevents the degradation of ubiquitinated proteins, affecting multiple signaling pathways. If C19orf43 stability or activity relies on proteasome-mediated regulation, bortezomib could indirectly inhibit its function. | ||||||
Thapsigargin | 67526-95-8 | sc-24017 sc-24017A | 1 mg 5 mg | $136.00 $446.00 | 114 | |
A SERCA pump inhibitor that leads to increased cytosolic calcium levels. Elevated intracellular calcium can disrupt various calcium-dependent signaling pathways. If C19orf43 requires calcium-mediated signaling for its activity, thapsigargin would lead to its inhibition. | ||||||